[Administration of nab-Paclitaxel for 9 metastatic breast cancer patients].

Related Articles

[Administration of nab-Paclitaxel for 9 metastatic breast cancer patients].

Gan To Kagaku Ryoho. 2012 Jul;39(7):1081-5

Authors: Sakaguchi K, Mizuta N, Imai A, Nakatsukasa K, Morita M, Soushi M, Taguchi T

Abstract
Nab-paclitaxel was administered to 9 patients with refractory advanced or recurrent breast cancer from 1 to 8 times(median 4)triweekly. The median cumulative dose was 775mg/m2(range 260-2, 000), and the median delivered dose intensity was 66. 7mg/m2/week(range 58. 3-86. 7). The response to treatment was CR in one patient, PR in 2 patients, SD in one patient, and PD in 4 patients. In one patient, treatment had to be suspended because of grade 3 peripheral neuropathy. The clinical benefit was 33%. All 4 PD patients were administered other salvage treatments and are alive. Adverse events included 6 case of neutropenia(grade 3-4 in 4 cases), grade 3 AST/ALT elevations in one patient, grade 3 myalgia in one patient. No case of febrile neutropenia was seen. All reactions were under control except for one patient with grade 3 peripheral neuropathy. Concurrent trastuzumab administration was safe also. In conclusion, nab-paclitaxel could be administered safely, and may contribute to the treatment of refractory advanced or recurrent breast cancer.

PMID: 22790043 [PubMed - in process]

peptide synthesis companies Natural products custom peptide price